Insights - Teva Pharmaceuticals (TEVA) purchased Auspex Pharmaceuticals this spring for $3.5 billion, primarily for access to the developmental SD-809 (deutetrabenazine), which was in mid-stage studies for the treatment of chorea associated with Huntingtonâ€™s disease, tardive dyskinesia, and Tourette syndrome. But the larger pharma company has a competitor nipping at its heels.Read now
How Do You Know When a Correction Has Run Its Course?
It's not easy. But the good news is - you don't have to....Read Now
As Bears Take a Victory Lap, Evaluating this Long Thesis
After a brutal session for the biotech sector (NBI dropped 6% for the day) ESPR fell another $3 in after...Premium